CD22 and colorectal carcinoma: The intestinal environment after intervention by specific strains induces various immune states and involves the related metabolic processes of gut microbiota derivatives, which can be used to further explore the molecular regulatory processes of different inhibitory co-receptors, such as CD22 and lipid metabolism, as well as arachidonic acid metabolism to reveal the precise mechanism of Zhang-LL in reversing CRC outcomes.